Fig. 4

Taprenepag increased the number of TPH-2⁺ neurons and improved the development of TCAs in fetuses exposed to VPA. (A) Schematic diagram for the neuronal bodies and axons of TPH-2⁺ neurons and the development of Netrin-G1a⁺ TCAs and section positions of different slices. VPA-exposed pregnant mice received VPA at E12.5 and drug treatment (0.05 mg/kg RU486 or 0.5 mg/kg taprenepag) at E13.5. The sections were observed 24 h after administration. (B) and (C) The mean fluorescence intensity of TPH-2⁺ neuron body immunofluorescence staining in the MRN and TPH-2⁺ axons in MFB. (n = 5 dams, respectively). (D) Immunofluorescence staining of the neuron bodies and axons of TPH-2⁺ neurons and Netrin-G1a⁺ TCAs. Statistics were calculated by one-way ANOVA with Dunnett’s post hoc test for (B) and (C). Statistical significance was denoted by *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. The graphs show the mean ± SEM